"bcl-X Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the bcl-2 protein family that plays a role in the regulation of APOPTOSIS and is a regulatory subunit for PROTEIN PHOSPHATASE 1. Two major isoforms of the protein exist due to ALTERNATIVE SPLICING of the BCL2L1 mRNA and are referred to as Bcl-XS and Bcl-XL.
| Descriptor ID |
D051020
|
| MeSH Number(s) |
D12.644.360.075.718.937 D12.776.476.075.718.875
|
| Concept/Terms |
bcl-X Protein- bcl-X Protein
- bcl X Protein
- bcl2-Like 1 Protein
- bcl2 Like 1 Protein
- bcl2L1 Protein
bcl-XS Protein- bcl-XS Protein
- bcl XS Protein
- bcl-Xshort Protein
- bcl Xshort Protein
- bcl-X(S) Protein
bcl-Xbeta Protein- bcl-Xbeta Protein
- bcl Xbeta Protein
- bcl-Xb Protein
- bcl Xb Protein
- bcl-x(beta) Protein
bcl-XL Protein- bcl-XL Protein
- bcl XL Protein
- bcl-Xlong Protein
- bcl Xlong Protein
- bcl-X(L) Protein
|
Below are MeSH descriptors whose meaning is more general than "bcl-X Protein".
Below are MeSH descriptors whose meaning is more specific than "bcl-X Protein".
This graph shows the total number of publications written about "bcl-X Protein" by people in this website by year, and whether "bcl-X Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 4 | 4 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 4 | 4 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "bcl-X Protein" by people in Profiles.
-
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 11 25; 12(1):6896.
-
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020 09 24; 136(13):1520-1534.
-
In?Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells. Cancer Invest. 2020 Jul; 38(6):349-355.
-
Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. Anticancer Drugs. 2017 11; 28(10):1141-1149.
-
Efficient generation of integration-free ips cells from human adult peripheral blood using BCL-XL together with Yamanaka factors. PLoS One. 2013; 8(5):e64496.
-
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun; 12(6):1140-50.
-
Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis. Cancer Biol Ther. 2011 Nov 01; 12(9):846-54.
-
Ceramide synthase-dependent ceramide generation and programmed cell death: involvement of salvage pathway in regulating postmitochondrial events. J Biol Chem. 2011 May 06; 286(18):15929-42.
-
Glutaredoxin regulates apoptosis in cardiomyocytes via NFkappaB targets Bcl-2 and Bcl-xL: implications for cardiac aging. Antioxid Redox Signal. 2010 Jun 15; 12(12):1339-53.
-
Neuroprotective role of erythropoietin by antiapoptosis in the retina. J Neurosci Res. 2009 Aug 01; 87(10):2365-74.